BioStrategies LC

Company Logo Goes Here

Contact: David Radin, PhD
Location: Jonesboro, Arkansas
Email: radin@biostrategies-lc.com
Tel: 870-897-7310
Website: http://www.biostrategies-lc.com

Company Profile

Industry Sector: Therapeutic drug development for rare genetic diseases

Company Overview: BioStrategies LC is a small startup biotech company founded by Drs, D. Radin and C. Cramer in 2007 to develop their innovative enzyme replacement drug delivery/targeting discoveries for the benefit of patients suffering from life terminating rare genetic diseases. The company's founders have previously developed cutting edge ERT technologies and have a continuing commitment to solve current treatment limitations that have reduced the efficacy of these drugs in hard to treat organs such as the brain, heart, and skeletal system.
Target Market(s): Physicians and pharmaceutical companies targeting patients suffering from currently incurable genetic rare diseases.

Key Value Drivers

Technology*: Novel enzyme replacement therapeutic drugs utilizing fusion proteins targeting hard to treat organs.

Competitive Advantage: BioStrategies unique proprietary fusion protein delivery technology provides an historic technical breakthrough in enzyme replacement therapy in facilitating the delivery of genetically deficient human enzymes to hard to treat organs of the body such as the CNS that have not been treated by previous drug technology.
Plan & Strategy: We have recently demonstrated proof of concept in showing drug efficacy in reducing cell pathology in brains of two animal disease models. We plan to take these drugs through preclinical development to IND approval by FDA within the next two years using primarily follow-on Phase II support from NIH SBIR grants.

Management

Leadership: David Radin, Managing Director, Carole Cramer, Scientific Director
During the next two year phase the company founders plan to hire outside management to facilitate preclinical and clinical drug development phases.
Scientific Advisory Board: We have begun to appoint a group of experts in all phases of biotech drug development to our new SAB.

Product Pipeline

1. Pipeline One: ERT for GM1 gangliosidosis, a fusion protein drug designed to deliver deficient enzyme to the brain. This drug has shown cellular efficacy in the animal disease model of this disease.
2. Pipeline Two: ERT for treating CNS pathology of MPSI patients. This drug has shown cellular behavioral efficacy in its animal disease model.
3. Pipeline Three: ERT for MPSIIIA, Sanfilippo Syndrome. This drug has shown efficacy in correcting pathology of this disease in cell cultures.